In recent years, several innovative therapies have been incorporated into the therapeutic landscape of NSCLC, such as TKIs targeting ALK, EGFR, or ROS1 or immunotherapies (in monotherapy or in combination with chemotherapy) in WT patients [1, 9, 11, 12]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.